For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
SSRIs probably reduce premenstrual symptoms
Vault Navigation
SSRIs probably reduce premenstrual symptoms
How effective and safe are selective serotonin reuptake inhibitors when used to treat premenstrual syndrome and premenstrual dysphoric disorder?
SSRIs are likely effective in reducing symptoms of PMS and PMDD, whether taken continuously or during the luteal phase, with continuous use showing slightly better results. The treatment helps with psychological, physical and functional symptoms, although effect sizes are generally small to moderate. SSRIs can reduce premenstrual symptoms significantly, and although not providing a cure, they could potentially reduce severe symptoms enough to improve quality of life.
However, SSRIs are associated with adverse effects (eg, gastrointestinal complications, nausea, fatigue, sexual dysfunction), which can impact quality of life. Long-term use can lead to persistent issues in these areas. Despite this, SSRIs remain a valuable option for managing PMDD and potentially PMS, especially in cases with severe symptoms.
Studies indicate a high relapse rate of premenstrual symptoms after discontinuing SSRIs, with 60% relapsing after 4 months and 41% after 12 months of sertraline therapy. Relapse risk is highest in women with severe baseline symptoms, regardless of treatment duration. These findings suggest the need for careful consideration of treatment length.
PMS affects 15–20% of women, leading to substantial distress and impairing daily functioning, with symptoms ranging from mood swings and depression to physical discomfort such as bloating and headaches. The severe form, PMDD, affects 3–8% of women and is recognised as a distinct medical condition.
SSRIs influence serotonin, a neurotransmitter involved in mood regulation. Since PMS symptoms are linked to hormonal fluctuations affecting neurotransmitters such as serotonin, SSRIs can help stabilise mood and reduce symptoms. Their rapid efficacy in PMS suggests they may target different receptor sites than those involved in traditional mood disorders.
Jespersen C, et al. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder. Cochrane Database Syst Rev 2024;8:CD001396. This review contains 34 trials with 4563 people.